The path to hepatitis C elimination: who are we leaving behind and why?
作者信息
Rockstroh Jurgen K, Swan Tracy, Chang Judy, Elamouri Fauzi, Lloyd Andrew R
机构信息
Department of Medicine I, University Hospital Bonn, Bonn, Germany.
GlobalHealth Consultant, Barcelona, Spain.
出版信息
J Int AIDS Soc. 2023 Jul;26(7):e26136. doi: 10.1002/jia2.26136.
Abstract
摘要
相似文献
1
The path to hepatitis C elimination: who are we leaving behind and why?
J Int AIDS Soc. 2023 Jul;26(7):e26136. doi: 10.1002/jia2.26136.
2
A National Hepatitis C Elimination Program in the United States: A Historic Opportunity.
JAMA. 2023 Apr 18;329(15):1251-1252. doi: 10.1001/jama.2023.3692.
3
[Elimination of hepatitis C virus in Denmark].
Ugeskr Laeger. 2020 Feb 24;182(9).
4
Hepatitis C Virus Elimination in the Human Immunodeficiency Virus-Coinfected Population: Leveraging the Existing Human Immunodeficiency Virus Infrastructure.
Infect Dis Clin North Am. 2018 Jun;32(2):407-423. doi: 10.1016/j.idc.2018.02.005.
5
Elimination of HCV in Russia: Barriers and Perspective.
Viruses. 2022 Apr 11;14(4):790. doi: 10.3390/v14040790.
6
The Road to Hepatitis C Virus Cure: Practical Considerations from a Health System's Perspective.
Infect Dis Clin North Am. 2018 Jun;32(2):481-493. doi: 10.1016/j.idc.2018.02.007.
7
Loss to follow-up in the hepatitis C care cascade: A substantial problem but opportunity for micro-elimination.
J Viral Hepat. 2020 Dec;27(12):1270-1283. doi: 10.1111/jvh.13399. Epub 2020 Sep 22.
8
Strategy for the Elimination of Hepatitis C in Cantabria.
Rev Esp Enferm Dig. 2020 Jul;112(7):565-570. doi: 10.17235/reed.2020.7108/2020.
9
Late presentation of chronic hepatitis C patients in the era of direct-acting antivirals-Data from the German Hepatitis C-Registry.
J Viral Hepat. 2021 Nov;28(11):1660-1664. doi: 10.1111/jvh.13576. Epub 2021 Jul 28.
10
Hepatitis C virus screening to reveal a better picture of infection.
Trends Microbiol. 2015 Jun;23(6):324-6. doi: 10.1016/j.tim.2015.02.007.
引用本文的文献
1
Hepatitis C Treatment Outcomes for Patients With Infective Endocarditis Treated by an Interdisciplinary Team.
Open Forum Infect Dis. 2025 Jul 21;12(8):ofaf431. doi: 10.1093/ofid/ofaf431. eCollection 2025 Aug.
2
Improving implementation of needle and syringe programmes to expand, scale up, and sustain evidence-based prevention interventions for HIV and hepatitis C in prisons.
Lancet Public Health. 2025 Jan;10(1):e63-e70. doi: 10.1016/S2468-2667(24)00275-5. Epub 2024 Dec 16.
3
Prevalence of blood-borne virus infections and uptake of hepatitis C testing and treatment in Australian prisons: the AusHep study.
Lancet Reg Health West Pac. 2024 Nov 21;53:101240. doi: 10.1016/j.lanwpc.2024.101240. eCollection 2024 Dec.
4
Impact of the COVID-19 pandemic on hepatitis C virus screening in provincial prisons in Montreal, Quebec, Canada.
Front Public Health. 2024 Jul 23;12:1380126. doi: 10.3389/fpubh.2024.1380126. eCollection 2024.
5
How Possible Is the Elimination of Viral Hepatitis? An Analysis Based on the Global Burden of Disease from Hepatitis B and C, 1990-2019.
Microorganisms. 2024 Feb 15;12(2):388. doi: 10.3390/microorganisms12020388.
本文引用的文献
1
Global reporting of progress towards elimination of hepatitis B and hepatitis C.
Lancet Gastroenterol Hepatol. 2023 Apr;8(4):332-342. doi: 10.1016/S2468-1253(22)00386-7. Epub 2023 Feb 8.
2
Interventions to enhance testing and linkage to treatment for hepatitis C infection for people who inject drugs: A systematic review and meta-analysis.
Int J Drug Policy. 2023 Jan;111:103917. doi: 10.1016/j.drugpo.2022.103917. Epub 2022 Dec 19.
3
Prison-based interventions are key to achieving HCV elimination among people who inject drugs in New South Wales, Australia: A modelling study.
Liver Int. 2023 Mar;43(3):569-579. doi: 10.1111/liv.15469. Epub 2022 Nov 14.
4
Treatment of Hepatitis C virus among people who inject drugs at a syringe service program during the COVID-19 response: The potential role of telehealth, medications for opioid use disorder and minimal demands on patients.
Int J Drug Policy. 2022 Mar;101:103570. doi: 10.1016/j.drugpo.2021.103570. Epub 2021 Dec 20.
5
Evaluation of hepatitis C treatment-as-prevention within Australian prisons (SToP-C): a prospective cohort study.
Lancet Gastroenterol Hepatol. 2021 Jul;6(7):533-546. doi: 10.1016/S2468-1253(21)00077-7. Epub 2021 May 7.
6
Hepatitis C elimination among people incarcerated in prisons: challenges and recommendations for action within a health systems framework.
Lancet Gastroenterol Hepatol. 2021 May;6(5):391-400. doi: 10.1016/S2468-1253(20)30365-4.
7
Age and gender-specific hepatitis C continuum of care and predictors of direct acting antiviral treatment among persons who inject drugs in Seattle, Washington.
Drug Alcohol Depend. 2021 Mar 1;220:108525. doi: 10.1016/j.drugalcdep.2021.108525. Epub 2021 Jan 11.
8
Hepatitis C virus elimination: laying the foundation for achieving 2030 targets.
Nat Rev Gastroenterol Hepatol. 2021 Feb;18(2):91-92. doi: 10.1038/s41575-020-00392-3.
9
Association Between Opioid Agonist Therapy and Testing, Treatment Uptake, and Treatment Outcomes for Hepatitis C Infection Among People Who Inject Drugs: A Systematic Review and Meta-analysis.
Clin Infect Dis. 2021 Jul 1;73(1):e107-e118. doi: 10.1093/cid/ciaa612.
10
A systematic review and meta-analysis of community and primary-care-based hepatitis C testing and treatment services that employ direct acting antiviral drug treatments.
BMC Health Serv Res. 2019 Oct 28;19(1):765. doi: 10.1186/s12913-019-4635-7.
Zotero 插件